Resverlogix Corp. (RVX.TO)
CAD 0.05
(12.5%)
CAD 0.05
(12.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 12.71 Million USD | -19.78% |
| 2021 | 15.84 Million USD | 356332.75% |
| 2020 | 4446.00 USD | -99.98% |
| 2019 | 22.57 Million USD | 14206.35% |
| 2018 | 157.81 Thousand USD | -99.62% |
| 2017 | 41.85 Million USD | 22.59% |
| 2016 | 34.14 Million USD | 70.66% |
| 2015 | 20 Million USD | 336.55% |
| 2014 | -8.45 Million USD | 39.74% |
| 2013 | -14.03 Million USD | 59.47% |
| 2012 | -34.63 Million USD | -240.64% |
| 2011 | 24.62 Million USD | 10.92% |
| 2010 | 22.2 Million USD | 0.56% |
| 2009 | 22.08 Million USD | 24.56% |
| 2008 | 17.72 Million USD | -28.56% |
| 2007 | 24.81 Million USD | 53.41% |
| 2006 | 16.17 Million USD | 145.27% |
| 2005 | 6.59 Million USD | 116.52% |
| 2004 | 3.04 Million USD | 116.34% |
| 2003 | 1.4 Million USD | 174.54% |
| 2002 | 512.82 Thousand USD | 1037.58% |
| 2001 | 45.08 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 4946.00 USD | -99.8% |
| 2023 Q2 | 1.44 Million USD | 29075.09% |
| 2023 Q3 | 1.1 Million USD | -23.7% |
| 2022 Q1 | 5.94 Million USD | 6.75% |
| 2022 Q2 | 2.03 Million USD | -65.75% |
| 2022 Q3 | 2.21 Million USD | 8.54% |
| 2022 FY | 12.71 Million USD | -19.78% |
| 2022 Q4 | 2.51 Million USD | 13.79% |
| 2021 Q2 | 3.4 Million USD | 106.93% |
| 2021 Q1 | 1.64 Million USD | 0.0% |
| 2021 FY | 15.84 Million USD | 356332.75% |
| 2021 Q4 | 5.57 Million USD | 6.56% |
| 2021 Q3 | 5.22 Million USD | 53.7% |
| 2020 Q3 | 3.35 Million USD | -19.06% |
| 2020 FY | 4446.00 USD | -99.98% |
| 2020 Q1 | 1.62 Million USD | -57.96% |
| 2020 Q2 | 4.14 Million USD | 155.8% |
| 2019 Q4 | 3.85 Million USD | -50.28% |
| 2019 Q3 | 7.75 Million USD | -16.91% |
| 2019 Q2 | 9.33 Million USD | -13.61% |
| 2019 Q1 | 10.8 Million USD | 15.44% |
| 2019 FY | 22.57 Million USD | 14206.35% |
| 2018 Q3 | 10.9 Million USD | 42.4% |
| 2018 Q4 | 9.36 Million USD | -14.16% |
| 2018 Q1 | 10.47 Million USD | -18.78% |
| 2018 Q2 | 7.66 Million USD | -26.85% |
| 2018 FY | 157.81 Thousand USD | -99.62% |
| 2017 FY | 41.85 Million USD | 22.59% |
| 2017 Q4 | 12.89 Million USD | 34.58% |
| 2017 Q3 | 9.58 Million USD | 7.54% |
| 2017 Q2 | 8.9 Million USD | -8.8% |
| 2017 Q1 | 9.76 Million USD | 1.12% |
| 2016 Q3 | 7.59 Million USD | 6.82% |
| 2016 Q1 | 7.62 Million USD | 60.5% |
| 2016 Q2 | 7.11 Million USD | -6.66% |
| 2016 FY | 34.14 Million USD | 70.66% |
| 2016 Q4 | 9.66 Million USD | 27.14% |
| 2015 Q3 | 4.14 Million USD | 18.57% |
| 2015 Q4 | 4.74 Million USD | 14.63% |
| 2015 FY | 20 Million USD | 336.55% |
| 2015 Q2 | 3.49 Million USD | 125.04% |
| 2015 Q1 | -13.95 Million USD | -824.45% |
| 2014 Q1 | -2.92 Million USD | -56.75% |
| 2014 FY | -8.45 Million USD | 39.74% |
| 2014 Q3 | 1.8 Million USD | 202.15% |
| 2014 Q4 | 1.92 Million USD | 6.76% |
| 2014 Q2 | -1.76 Million USD | 39.62% |
| 2013 FY | -14.03 Million USD | 59.47% |
| 2013 Q3 | -2.17 Million USD | 69.24% |
| 2013 Q4 | -1.86 Million USD | 14.21% |
| 2013 Q2 | -7.07 Million USD | 24.83% |
| 2013 Q1 | -9.4 Million USD | -12.7% |
| 2012 FY | -34.63 Million USD | -240.64% |
| 2012 Q4 | -8.34 Million USD | -200.69% |
| 2012 Q3 | 8.28 Million USD | -3.62% |
| 2012 Q2 | 8.59 Million USD | 25.11% |
| 2012 Q1 | 6.87 Million USD | 25.37% |
| 2011 Q4 | 5.48 Million USD | -21.36% |
| 2011 FY | 24.62 Million USD | 10.92% |
| 2011 Q2 | 5.3 Million USD | -21.49% |
| 2011 Q3 | 6.97 Million USD | 31.4% |
| 2011 Q1 | 6.75 Million USD | 48.32% |
| 2010 Q3 | 5.37 Million USD | 1.14% |
| 2010 Q4 | 4.55 Million USD | -15.21% |
| 2010 FY | 22.2 Million USD | 0.56% |
| 2010 Q1 | 5.58 Million USD | -29.25% |
| 2010 Q2 | 5.31 Million USD | -4.81% |
| 2009 Q2 | 4.62 Million USD | 24.01% |
| 2009 Q4 | 7.88 Million USD | 102.04% |
| 2009 Q3 | 3.9 Million USD | -15.63% |
| 2009 Q1 | 3.73 Million USD | -24.18% |
| 2009 FY | 22.08 Million USD | 24.56% |
| 2008 Q3 | 4.71 Million USD | 10.13% |
| 2008 Q1 | 6.3 Million USD | 9.54% |
| 2008 Q2 | 4.28 Million USD | -32.03% |
| 2008 Q4 | 4.92 Million USD | 4.28% |
| 2008 FY | 17.72 Million USD | -28.56% |
| 2007 Q2 | 5.71 Million USD | -28.28% |
| 2007 Q4 | 5.75 Million USD | -18.5% |
| 2007 Q3 | 7.06 Million USD | 23.49% |
| 2007 Q1 | 7.97 Million USD | 112.18% |
| 2007 FY | 24.81 Million USD | 53.41% |
| 2006 FY | 16.17 Million USD | 145.27% |
| 2006 Q4 | 3.75 Million USD | 31.94% |
| 2006 Q3 | 2.84 Million USD | 57.55% |
| 2006 Q1 | 2.1 Million USD | 57.0% |
| 2006 Q2 | 1.8 Million USD | -14.22% |
| 2005 Q2 | 1.17 Million USD | 12.7% |
| 2005 FY | 6.59 Million USD | 116.52% |
| 2005 Q4 | 1.34 Million USD | -26.69% |
| 2005 Q3 | 1.83 Million USD | 56.41% |
| 2005 Q1 | 1.03 Million USD | 7.35% |
| 2004 Q4 | 967.72 Thousand USD | 70.84% |
| 2004 Q2 | 450.06 Thousand USD | -37.51% |
| 2004 Q1 | 720.22 Thousand USD | 203.66% |
| 2004 FY | 3.04 Million USD | 116.34% |
| 2004 Q3 | 566.44 Thousand USD | 25.86% |
| 2003 Q3 | 147.58 Thousand USD | -48.46% |
| 2003 Q2 | 286.37 Thousand USD | 15.36% |
| 2003 FY | 1.4 Million USD | 174.54% |
| 2003 Q4 | 237.17 Thousand USD | 60.7% |
| 2003 Q1 | 248.24 Thousand USD | 110.21% |
| 2002 Q3 | 13.73 Thousand USD | -48.71% |
| 2002 Q4 | 118.09 Thousand USD | 759.93% |
| 2002 FY | 512.82 Thousand USD | 1037.58% |
| 2002 Q1 | 5022.13 USD | 0.0% |
| 2002 Q2 | 26.77 Thousand USD | 433.16% |
| 2001 FY | 45.08 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -43.851% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | 66.48% |
| Helix BioPharma Corp. | 9.35 Million CAD | -35.856% |
| Microbix Biosystems Inc. | 10.21 Million CAD | -24.411% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | 35.351% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -91.273% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | 62.381% |
| Sernova Corp. | 41.13 Million CAD | 69.094% |